Myeloid-targeting immunotherapies overcome inhibitory barriers in immune-evasive neuroblastoma. Read more about Myeloid-targeting immunotherapies overcome inhibitory barriers in immune-evasive neuroblastoma.
RORγt eTACs mediate oral tolerance and Treg induction. Read more about RORγt eTACs mediate oral tolerance and Treg induction.
Tumor cell heterogeneity drives spatial organization of the intratumoral immune response. Read more about Tumor cell heterogeneity drives spatial organization of the intratumoral immune response.
Intravital imaging of pulmonary lymphatics in inflammation and metastatic cancer. Read more about Intravital imaging of pulmonary lymphatics in inflammation and metastatic cancer.
Baseline colitogenicity and acute perturbations of gut microbiota in immunotherapy-related colitis. Read more about Baseline colitogenicity and acute perturbations of gut microbiota in immunotherapy-related colitis.
Targeting CD206+ macrophages disrupts the establishment of a key antitumor immune axis. Read more about Targeting CD206+ macrophages disrupts the establishment of a key antitumor immune axis.
Phosphatidylserine phospholipase A1 enables GPR34-dependent immune cell accumulation in the peritoneal cavity. Read more about Phosphatidylserine phospholipase A1 enables GPR34-dependent immune cell accumulation in the peritoneal cavity.
Interleukin-33-activated basophils promote asthma by regulating Th2 cell entry into lung tissue. Read more about Interleukin-33-activated basophils promote asthma by regulating Th2 cell entry into lung tissue.
Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer. Read more about Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer.
Human inherited PD-L1 deficiency is clinically and immunologically less severe than PD-1 deficiency. Read more about Human inherited PD-L1 deficiency is clinically and immunologically less severe than PD-1 deficiency.
